iBio, Inc. Changes Certifying Accountant
Ticker: IBIO · Form: 8-K · Filed: 2024-02-21T00:00:00.000Z
Sentiment: neutral
Topics: auditor-change, corporate-governance
TL;DR
**iBio changed its auditor, a routine but notable event for financial transparency.**
AI Summary
iBio, Inc. filed an 8-K on February 21, 2024, reporting a change in its certifying accountant. The earliest event reported was February 15, 2024. The filing indicates a change in the company's auditor, which is a standard disclosure for public companies.
Why It Matters
Changes in a company's auditor can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, impacting investor confidence.
Risk Assessment
Risk Level: low — This 8-K filing only reports a change in the certifying accountant, which is a common administrative event and does not inherently indicate significant financial risk.
Key Players & Entities
- iBio, Inc. (company) — Registrant
- February 15, 2024 (date) — Date of earliest event reported
- February 21, 2024 (date) — Filing date
- 001-35023 (dollar_amount) — Commission File Number
- 26-2797813 (dollar_amount) — IRS Employer Identification No.
FAQ
What is the purpose of this 8-K filing by iBio, Inc.?
The 8-K filing by iBio, Inc. is to report a 'Changes in Registrant's Certifying Accountant' and 'Financial Statements and Exhibits' as per Item Information.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 15, 2024.
What is iBio, Inc.'s Commission File Number?
iBio, Inc.'s Commission File Number is 001-35023.
Where are iBio, Inc.'s principal executive offices located?
iBio, Inc.'s principal executive offices are located at 8800 HSC Parkway, Bryan, Texas 77807.
What is the Central Index Key (CIK) for iBio, Inc.?
The Central Index Key (CIK) for iBio, Inc. is 0001420720.
Filing Stats: 1,002 words · 4 min read · ~3 pages · Grade level 14.3 · Accepted 2024-02-21 16:55:17
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value per share IBIO NYSE Americ
Filing Documents
- ibio-20240215x8k.htm (8-K) — 36KB
- ibio-20240215xex16d1.htm (EX-16.1) — 3KB
- 0001420720-24-000008.txt ( ) — 161KB
- ibio-20240215.xsd (EX-101.SCH) — 4KB
- ibio-20240215_def.xml (EX-101.DEF) — 3KB
- ibio-20240215_lab.xml (EX-101.LAB) — 14KB
- ibio-20240215_pre.xml (EX-101.PRE) — 10KB
- ibio-20240215x8k_htm.xml (XML) — 5KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant (a) Engagement of New Independent Registered Public Accounting Firm The Audit Committee (the "Audit Committee") of iBio, Inc. (the "Company"), conducted a competitive process to determine the Company's independent registered public accounting firm commencing with the audit of the Company's books and financial records for the year ending June 30, 2024. The Audit Committee invited several independent registered public accounting firms to participate in this process. Following review of proposals from the independent registered public accounting firms that participated in the process, on February 15, 2024, upon recommendation from management, the Audit Committee approved the engagement of Grassi & Co., CPAs, P.C. ("Grassi") as the Company's independent registered public accounting firm for the Company's fiscal year ending June 30, 2024. On February 20, 2024, the Company entered into an engagement letter with Grassi and engaged Grassi as the Company's independent registered public accounting firm effective immediately. During the fiscal years ended June 30, 2023 and June 30, 2022, and the subsequent interim periods through February 20, 2024, neither the Company nor anyone on its behalf has consulted with Grassi regarding: (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided to the Company that Grassi concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions; or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K. (b) Resignation of Previous Independent Regis
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 16.1 Letter from CohnReznick LLP dated February 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 21, 2024 IBIO, INC. By: /s/ Marc A. Banjak Name: Marc A. Banjak Title: General Counsel and Corporate Secretary